Business
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
BOSTON & MONTREAL, January 20, 2026--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the "Loan Agreement") with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene’s balance sheet
About this update from Hercules Capital, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b077b5927d9d9ec5013498890cc0e159"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TcQak36E4Ap8CV1k25p5NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b077b5927d9d9ec5013498890cc0e159","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0cfyefnMc455Sd4Fqd9mBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b077b5927d9d9ec5013498890cc0e159","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"$25 million advanced at close of the amendment to refinance existing debt facility","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & MONTREAL, January 20, 2026--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the "Loan Agreement") with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene’s balance sheet in preparation for its planned Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for detalimogene voraplasmid as a treatment for high-risk, Bacillus Calmette-Guérin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC") with carcinoma in situ ("CIS") in the second half of 2026, and the potential commercial launch of detalimogene should it receive FDA approval.","length":1021,"tagName":"p"},{"type":"text","content":""This additional access to capital strengthens our balance sheet and provides us financial flexibility as we plan for a BLA filing for detalimogene in the secon...